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Advanced or metastatic disease is common in both oesophagogastric and colorectal cancers, with poor 5-year survival despite
palliative chemotherapy. We have investigated the sensitivity of gastrointestinal tumours to gemcitabine in combination with
mitomycin C (GeM), using a modified ex vivo ATP-based tumour chemosensitivity assay (ATP-TCA). Tumour material from 41
colorectal and 22 oesophagogastric cancers were assessed. The GeM combination showed variable but definite activity in most of the
samples tested. The results show that GeM achieves 495% inhibition at concentrations within the range achievable clinically in 60%
of colorectal tumours (21 out of 35) and 38% of oesophagogastric tumours (five out of 13) tested. We did not identify any significant
difference in sensitivity using concurrent or sequential exposure of tumour-derived cells to these two drugs. The results from this
study suggest that GeM may be a useful combination in the treatment of advanced gastrointestinal malignancy.
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Colorectal adenocarcinoma (CRC) is the second most common
cause of cancer death in the western world. Despite potentially
curable surgical treatment in 70–80%, half of all patients will die
from metastatic disease, often within 5 years of diagnosis.
Palliative chemotherapy may reduce the symptoms, extend
survival from 6 to 12 months, and despite treatment-related
adverse effects, often improve or at least maintain the quality of
life (Nordic Gastrointestinal Tumour Adjuvant Therapy Group,
1992). In the UK, the current NICE guidance on chemotherapy in
advanced colorectal disease (NICE, 2002) advocates the use of 5-
fluorouracil (5FU) with folinic acid (FA) as first line therapy. This
combination achieves response rates of 18–22% and overall
survivals of 12–15 months (de Gramont et al, 2000; Maiello et al,
2000). Combinations using newer agents such as irinotecan and
oxaliplatin achieve higher response rates of up to 50% and longer
median overall survivals (Douillard et al, 2000; Saltz et al, 2000;
Grothey et al, 2002). However, the newer agents, especially in
combination with 5FU/FA, are associated with greater toxicity,
which may be severe and dose-limiting.
Oesophageal and gastric cancers together account for 7% of all
cancer-related deaths. Palliative treatment may be achieved with
chemotherapy, radiotherapy or chemoradiation. A number of
chemotherapy regimens are in use. Most are triple therapies
incorporating 5FU and cisplatin with either epirubicin or
paclitaxel. Response rates of 48–70% have been achieved (Kim
et al, 1993; Ilson et al, 1998) with a 2-year survival of 13.5%
(Findlay et al, 1994); however, in general, the responses are often
short lived and these treatments are associated with varying
degrees of toxicity.
Recently, we investigated the chemosensitivity of colorectal and
oesophagogastric adenocarcinomas (Mercer et al, 2003; White-
house et al, 2003) using a modified ex vivo ATP-based tumour
chemosensitivity assay (ATP-TCA) (Andreotti et al, 1995; Cree
et al, 1996). We demonstrated considerable differences in
sensitivity between individual tumours of both tumour types.
Mitomycin C (MMC) has been used in the treatment of
gastrointestinal tumours for many years, although it is not now
the most commonly used drug due to serious pulmonary, renal
and haematological toxicities, which tend to occur with over-
dosage. It remains useful in the treatment of metastatic gastro-
intestinal tumours, usually in combination with 5-FA. Gemcitabine
is licensed for use in pancreatic and non-small-cell lung cancers. It
has also shown preclinical and clinical activity in several other
solid tumours, including ovarian, head and neck and breast
cancers (Carmichael et al, 1995; Markman, 2002). However, phase
I/II trials of single-agent gemcitabine have not demonstrated any
activity in advanced colorectal and gastric cancers (Moore et al,
1992; Christman et al, 1994; Mani et al, 1998). We therefore wished
to test this combination on further gastrointestinal tumour
samples and investigate any schedule dependency.
MATERIALS AND METHODS
Tumours
Material from 41 colorectal and 22 oesophagogastric tumours was
tested. All the colorectal tumours were previously untreated. Six
of the oesophagogastric tumours had received neoadjuvant
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schemotherapy with epirubicinþcisplatinþ5-FA (ECF). The
median age of patients undergoing colorectal resection was 70
years (range 39–86) and for oesophagogastric resection was 69
years (range 39–87). The local ethics committee approval for the
use of tissue or cells not required for diagnosis was obtained, and
informed consent gained from all patients.
ATP-tumour chemosensitivity assay
The ATP-tumour chemosensitivity assay (ATP-TCA) was per-
formed as previously described (Andreotti et al, 1995; Cree, 1998).
Tumour samples were transported to the laboratory in transport
medium consisting of Dulbecco’s modified Eagle’s medium
(Sigma, Poole, UK; D5671), minced and dissociated overnight in
collagenase (Sigma; C8051). The concentration of collagenase used
was 0.75mgml
 1 for oesophagogastric samples and 1.5mgml
 1
for colorectal samples. If necessary, the samples were purified
using Ficoll-hypaque density centrifugation (Sigma; 1077-1) to
remove red blood cells and cell debris. The remaining cells were
resuspended in antibiotic containing serum-free complete assay
medium (CAM) (DCS Innovative Diagnostik Systeme, Hamburg,
Germany) at 200000cellsml
 1. Additional amphotericin B
(2.5mgml
 1) was added to the CAM for the oesophagogastric
samples, and amphotericin B (2.5mgml
 1) and metronidazole
(1mgml
 1) were added to the CAM for the colorectal samples, as
previously described (Whitehouse et al, 2003). 96-well polypropy-
lene plates (Corning-Costar, High Wycombe, UK) were prepared
with 100ml of CAM, to which the drugs were added at six
concentrations in triplicate. Two internal controls were included in
each plate: a maximum inhibitor (MI) that kills all the cells
resulting in a zero ATP count, and a medium only (MO) without
any drugs. After 6 days incubation at 371C with 5% CO2, the cells
were lysed with a detergent-based tumour cell extraction reagent
(DCS Innovative Diagnostik Systeme). A volume of 50ml from each
well was transferred to the wells of a 96-well white plate (Thermo
Life Sciences, Basingstoke, UK), to which 50ml of luciferin-
luciferase counting reagent (DCS Innovative Diagnostik Systeme)
was added. The ATP content of each well was quantified by the
amount of light produced in a microplate luminometer (Bethold
MPLX). The results are expressed as the percent inhibition
achieved at each concentration tested, calculated as: % inhibi-
tion¼1 (test MI)/(MO MI) 100.
Drugs
Mitomycin C (Kyowa, London, UK) and Gemcitabine (Eli Lilly,
Basingstoke, UK) were obtained as vials for injection, and made up
according to the manufacturer’s instructions. Both MMC and
gemcitabine were stored as aliquots at  201C (Hunter et al, 1994).
The 100% test drug concentrations (TDCs) used were calculated
from pharmacokinetic data to approximate concentrations clini-
cally achievable in the patient (Andreotti et al, 1995). While this
has inevitable inaccuracies, the 100% TDC of MMC was 0.7mgml
 1
(2.0mM) and the 100% TDC of gemcitabine was 12.5mgml
 1
(40mM). Drug dilutions were prepared in the plates from freshly
made up 800% TDC drug solutions. Combinations of drugs were
made by adding both drugs, each at its 800% TDC. In
combinations tested in the assay, drugs are present at decreasing
concentrations in a constant ratio.
Sequential studies were performed by testing (i) MMC and
gemcitabine, both added at 0h; (ii) MMC at 0h followed by the
addition of gemcitabine at 6h; (iii) MMC at 0h and gemcitabine at
24h; and (iv) gemcitabine at 0h with MMC added at 24h.
Data analysis
Data from each assay were transferred directly from the
luminometer to an Excel 2000 spreadsheet (Microsoft). A number
of indices of efficacy can be calculated from the data, including the
IC90. The natural logarithmic sum index (IndexSUM), calculated by
summing the percentage inhibition at each concentration, has been
found to allow the best comparison of responses between samples
(Hunter et al, 1993). In addition, the area under the concentra-
tion–inhibition curve (IndexAUC) and the percentage of tumours
achieving 95% inhibition have been calculated. Combination
effects were assessed using the method established by Poch et al
(1995), as previously used with the ATP-TCA (Kurbacher et al,
1997). This is used in preference to the Chou and Talalay method,
because it is better able to deal with drugs which produce a shallow
dose–response curve (Chou and Talalay, 1984). However, we have
also performed a Chou and Talalay analysis, where the combina-
tion index (CI) was determined at 90% cell death, and was defined
as follows:
CIAþB ¼½ ð DA=AþBÞ=DA þ½ ð DB=AþBÞ=DB 
þ½ alphaðDA=AþB DB=AþBÞ=DADB 
where CIAþB¼CI for a fixed effect (F¼90%) for the combination
of cytotoxic A and cytotoxic B; DA/AþB¼concentration of
cytotoxic A in the combination AþB, giving an effect F; DB/
AþB¼concentration of cytotoxic B in the combination AþB,
giving an effect F; DA¼concentration of cytotoxic A alone, giving
an effect F; DB¼concentration of cytotoxic B alone, giving an
effect F. alpha¼parameter with value 0 when A and B are mutually
exclusive, and 1 when A and B are mutually nonexclusive.
The combination index indicated: synergism o0.8; additivity
40.8 and o1.2; antagonism o1.2; slight synergistic and additive
cytotoxic activity for values of 0.8 and 1.2, respectively.
RESULTS
Evaluable results were obtained from 60 out of 63 tumours, giving
an evaluability rate of 95%. Three tumours were not evaluable due
to contamination of the cell culture. Despite the addition of extra
antibiotics during specimen preparation, contamination is a
problem with such tissue and these samples are technically
challenging (Whitehouse et al, 2003).
The single-agent results are shown in Figure 1 and Table 1.
There is considerable heterogeneity between tumours for these two
drugs, with sensitivity to MMC in 71% of the oesophagogastric
tumours (15 out of 21) and 59% of the colorectal tumours (21 out
of 39). For comparison between drugs and tumours, an IndexSUM
of o300, representing an average 50% inhibition across all
concentrations tested, has been used to indicate sensitivity, as
previously published (Hunter et al, 1993; Cree et al, 1999). Despite
these apparently encouraging results, MMC alone achieves 495%
inhibition at clinically achievable concentrations in just 14% of
oesophagogastric tumours (three out of 21) and 10% of colorectal
tumours (four out of 39) tested. Gemcitabine alone is active on the
basis of an IndexSUM o300 in 42% of oesophagogastric tumours
and 50% of colorectal tumours. However, it tends to have a very
shallow dose–response curve and only rarely produced 495%
inhibition at clinically achievable concentrations: 6% of oesopha-
gogastric tumours (one out of 17) and 3% of colorectal tumours
(one out of 38).
In contrast to the single-agent results, gemcitabine in combina-
tion with MMC (GeM) achieves 495% inhibition at clinically
achievable concentrations in 60% of colorectal tumours (21 out of
35) and 38% of oesophagogastric tumours (five out of 13) tested
(Table 1). The use of an IndexSUM o300 threshold for combina-
tions tends to overstate the sensitivity, and it is not surprising that
100% of the tumours tested reached this threshold for sensitivity,
as applied to single agents. Even when the IndexSUM is decreased to
o200, GeM is active in 100 and 89% of oesophagogastric and
colorectal tumours, respectively. Figure 1 shows this as a shift in
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sactivity towards the lower concentrations tested. In oesophageal
tumours, the addition of gemcitabine decreased the MMC IC90
from 3.89 to 0.86mM, and for colorectal tumours the MMC IC90 was
decreased from 3.73 to 0.96mM. Using the Chou and Talalay
method, this equates for oesophageal cancers to a CI90 of 0.41
(synergism) and for colorectal cancers to a CI90 of 0.44
(synergism).
The CRC example shown in Figure 2A shows the advantage of
the GeM combination over the individual agents in terms of
inhibition. When analysed by the method of Poch et al (1995), by
which the observed effect at each concentration tested is compared
with that expected, the effect is greater than additive (Figure 2B).
Schedule experiments of gemcitabine and MMC are shown in
Figure 3. These experiments were performed, in at least triplicate,
by adding 6.25–200% TDC of gemcitabine to 6.25–200% TDC of
MMC at 0, 6 and 24h. Mitomycin C was also added to gemcitabine
at 24h. There was no apparent difference in inhibition between the
Figure 1 Summary of the heterogeneity of activity in the ATP-TCA to
MMC, gemcitabine, and the combination (GeM) in (A) colorectal cancer
(n¼39), and (B) oesophagogastric cancer (n¼21). The IndexSUM is a
parameter describing the concentration–inhibition curve for each drug, or
combination in a single number. Using the IndexSUM o300 to indicate
sensitivity, GeM is clearly more active than either single agent.
Table 1 Summary of sensitivity data (using an arbitrary threshold of sensitivity defined as a
IndexSUMo300 for six concentrations used)
Drug No. assessed No. sensitive
Sensitivity (%)
(Index o300) 495% Inhibition (%)
Oesophagogastric cancer
Mitomycin C 21 15 71 14 (three out of 21)
Gemcitabine 17 7 42 6 (one out of 17)
Mitomycin C+Gemcitabine 13 13 100 38 (five out of 13)
Colorectal cancer
Mitomycin C 39 21 54 10 (four out of 39)
Gemcitabine 38 19 50 3 (one out of 38)
Mitomycin C+gemcitabine 35 35 100 60 (21 out of 35)
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Figure 2 (A) Inhibition–concentration curve in a colorectal tumour
sample. (B) By the method of Poch et al. (1995), the observed effect of the
combination at each concentration is greater than the expected effect
(independent action).
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sdifferent schedules (93.84–95.84% tumour growth inhibition at
100% TDC), although gemcitabine added to MMC at 24h did
produce the lowest growth inhibition of 93.84%).
DISCUSSION
These results show that, ex vivo, the combination of gemcitabine
and MMC (GeM) is more effective than the single agents alone,
when tested on gastrointestinal tumours. Our previous studies
have shown this to be the most active combination in the assay,
when tested alongside standard treatment regimens (Mercer et al,
2003; Whitehouse et al, 2003), with 38% of oesophagogastric
tumours and 60% of colorectal tumours tested, showing 495%
inhibition in the ex vivo ATP-TCA. We believe the 95% inhibition
figure to be important, as this is the level of tumour cell kill
required for most logarithmic kill models to show effects (Goldie
and Coldman, 1979). While these data may not of course translate
into clinical efficacy of similar magnitude, it does provide a basis
for the clinical investigation of this combination in gastrointestinal
tumours. The difference in sensitivity between the two tumours
may be related to tumour type, to the proportion of previously
treated oesophageal cancer samples included in the study, or to the
necessary inclusion of metronidazole in the cell cultures from
colorectal tumours. In a previous study (Whitehouse et al, 2003),
we tested the antibiotics at varying concentrations in combination
with chemotherapeutic agents against cell lines and tumour
samples, and were unable to show any additional toxicity at the
concentrations used in this study. We believe that the effect of
previous treatment may be a major factor in this unexpected
difference between these two tumour types.
Mitomycin C has been used in the treatment of gastrointestinal
malignancies for over 30 years, and has been shown to be relatively
safe and effective (Chester et al, 2000), although very rarely
patients may develop the haemolytic–uraemic syndrome, usually
at very high doses (Catalano et al, 2002; Gundappa et al, 2002).
Pulmonary and renal toxicities are also a problem in some
patients, again usually at high cumulative doses. It is a DNA-
damaging drug, inhibiting DNA synthesis by crosslinking adeno-
sine and guanine under anaerobic conditions (Spanswick et al,
1998). Single-agent MMC has produced response rates of up to
23% in colorectal cancer (Moertel et al, 1968; Moore et al, 1968).
The combination of MMC and 5FU has shown synergistic growth
inhibition of cell lines (Sartorelli and Booth, 1965), including
colorectal cancer cell lines (Russello et al, 1989). A randomised
controlled trial in colorectal cancer found that MMC in combina-
tion with protracted venous infusion (PVI) 5FU increased the
response rates to 54%, but with no benefit to overall and 1-year
survival (Ross et al, 1997). A further phase III study confirmed an
improved response rate with a survival benefit at 2 years (Price
et al, 1999). Mitomycin C has been used in combination therapy of
oesophagogastric cancers. Although initial response rates of 40%
were quoted for treatment with FAM (5FU, doxorubicin and MMC)
(MacDonald et al, 1979), no benefit has been demonstrated from
the addition of MMC to 5FU (Tebbutt et al, 2002). MCF (MMC,
cisplatin and 5FU) has no survival advantages over standard
treatment with ECF (epirubicin, cisplatin, 5FU) (Ross et al, 2002).
Gemcitabine is an antimetabolite cytidine analogue with a
number of mechanisms of cytotoxicity. Intracellular phosphoryla-
tion to its active metabolite results in (a) prevention of DNA
synthesis by inhibiting DNA polymerases and by competing with
deoxycytidine triphosphate, (b) inhibition of ribonucleotide
reductase, depleting deoxynucleotide pools and favouring incor-
poration of gemcitabine into DNA, (c) incorporation into DNA,
decreasing the accuracy of DNA replication and repair, and (d)
incorporation into RNA. It should be noted that the effect of
gemcitabine on ribonucleotide reductase could affect ATP levels,
possibly as part of its cytostatic effect, though gemcitabine is
inactive against many solid tumours (Neale et al, 1999) and this
does not seem to be a problem for its use in the assay.
Gemcitabine, which is cell cycle specific, and well tolerated
clinically, is an attractive drug for use in combination with DNA-
damaging agents (Huang et al, 1991); particularly it has been
shown to modulate the activity of a wide range of DNA-damaging
agents, including platinum (Peters et al, 1995; Sandler et al, 2000)
and alkylating agents (Neale et al, 1999). We have not investigated
the exact mechanism of modulation of MMC sensitivity with
gemcitabine, but this may be due to inhibition of repair of
alkylating agent-induced DNA adducts, an increase in DNA
double-strand breaks or changes in dNTP pools. Studies of
gemcitabine in combination with cisplatin are based on this
mechanism of action (Cardenal et al, 1999). This study raises the
question as to whether other alkylating agents might be effective in
combination with gemcitabine in gastrointestinal cancer.
There are very few in vitro studies of gemcitabine and MMC.
The combination was found to be synergistic after 4h on a Lewis
lung cancer cell line, without any increase in DNA double-strand
breaks (van Moorsel et al, 1997). Similarly, MMC and gemcitabine
had a synergistic effect, when administered concurrently, but not
sequentially, on the HT29 human colon cancer cell line (Aung et al,
2000), suggesting that gemcitabine could be beneficial in the
treatment of cancers sensitive to MMC.
Clinical studies are also few in number: intravenous and intra-
arterial locoregional treatment with MMC and gemcitabine has
been found to be highly effective with improved response rates in
pancreatic cancer (Klapdor et al, 2000). This drug combination
(median total dose MMC 32mgm
 2) has been administered
together with radiotherapy with tolerable toxicity (Korneck et al,
2001).
In this study, we have not demonstrated any schedule-specific
alterations in chemosensitivity; there were no protective effects on
the cells of prior addition of gemcitabine as we have previously
reported for treosulfanþgemcitabine (Neale et al, 1999). It should
be noted that the nature of the assay means that, in all
experiments, the cells were exposed to the combination for at
least 5 days. However, a study of MMC and gemcitabine on the
HT29 human colon cancer cell line showed simultaneous exposure
to be necessary to demonstrate synergism (Aung et al, 2000). The
effect of gemcitabine in combination with other alkylating and
platinum agents has also been shown to be time-dependent
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Figure 3 Schedule studies of gemcitabine in combination with MMC. No
schedule dependency has been demonstrated.
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s(Braakhuis et al, 1995; Neale et al, 1999; van Moorsel et al, 2000).
Since simultaneous administration is generally preferable to
patients and oncology units, it would probably be reasonable to
give both drugs together in future clinical studies.
These results demonstrate that gemcitabineþMMC (GeM) is
effective ex vivo against tumour-derived cells from both oesopha-
geal and CRCs. There is little evidence of schedule dependency and
simultaneous administration should be feasible. These results have
encouraged us to explore the GeM regimen further in a phase I/II
clinical trial to establish its safety and efficacy in metastatic
gastrointestinal cancer.
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